Journal of Cancer Research and Therapeutics Close
 

Figure 2: Antiproliferative profile of FCX in prostate and colon cancer cell lines. (a) GI50 for FCX and gemcitabine in LNCaP cells. (b) GI50 of FCX in normal nontumorigenic colon cancer cells. (c) GI50 of FCX in LNCaP and PC3 cells (d) GI50 of FCX in HCT-8 and HT-29 colon cancer cells

Figure 2: Antiproliferative profile of FCX in prostate and colon cancer cell lines. (a) GI<sub>50</sub> for FCX and gemcitabine in LNCaP cells. (b) GI<sub>50</sub> of FCX in normal nontumorigenic colon cancer cells. (c) GI<sub>50</sub> of FCX in LNCaP and PC3 cells (d) GI<sub>50</sub> of FCX in HCT-8 and HT-29 colon cancer cells